Would you consider using sotorasib first line in patient with metastatic KRAS G12C NSCLC who declines chemotherapy?
Answer from: Medical Oncologist at Academic Institution
This would be outside the scope of available data and current FDA approval. Both CodeBreaK100 and CodeBreaK 200 (presented at ESMO) included only patients previously treated with either chemotherapy, immunotherapy, or both. I would generally stick to standard first line options for these patients, e...
Sign in or Register to read more